Research programme: protein kinase inhibitors - Asana BioSciences

Drug Profile

Research programme: protein kinase inhibitors - Asana BioSciences

Alternative Names: ASN-006; ASN-007; ASN007A

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Mitogen-activated protein kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Jan 2018 The US FDA approves IND application for ASN 007 in Cancer
  • 26 Oct 2017 Preclinical pharmacodynamics data in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-2017)
  • 26 Oct 2017 Asana Biosciences plans a phase I trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top